Life Healthcare Group Holdings Limited · JSE:LHC
Life Healthcare — ABSA Healthcare Conference 2021
16 slides from Life Healthcare's conference presentation, Feb 12, 2021
Slide 1: ABSA Healthcare Conference
ABSA HEALTHCARE CONFERENCE 11 - 12 FEBRUARY 2021
Slide 2: Vision and Strategic Focus Areas
2 VISION AND STRATEGIC FOCUS AREAS Our vision is to be a global, people-centred, diversified healthcare organisation Clinical Global Diversified excellence, healthcare offering analytics & provider technology 1 Offering an 2 With a growing 3 Focus on our integrated share of revenue employees, clinic
Slide 3: Strategic Pillars
3 STRATEGIC PILLARS QUALITY EFFICIENCY SUSTAINABILITY GROWTH Deliver cost-effective care Effectively engage with Deliver market-leading through our employees, Continue to grow our our stakeholders to quality care and clinicians, efficient businesses, while ensure our long-term patient experience pro
Slide 4: FY2020 Group Overview: A Global & Diversified Healthcare Group
4 FY2020 | GROUP OVERVIEW WHAT HAVE I INHERITED? A GLOBAL & DIVERSIFIED HEALTHCARE GROUP Southern United Europe & Poland India Africa Kingdom US 68% revenue 13% revenue 13% revenue 6% revenue disposed Hospitals 49 Hospitals 42 Facilities 12 Hospitals 8 240 beds 582 beds 2 375 beds Acute Complementar
Slide 5: Continued Progress in Diversifying Revenue Mix
5 FY2020 | GROUP OVERVIEW CONTINUED PROGRESS IN DIVERSIFYING REVENUE MIX GEOGRAPHICALLY AND AWAY FROM ACUTE CARE SERVICES Revenue mix (%) 2010 2015 2020 7% 4% 6% 32% 37% 100% 93% 96% 94% 68% 63% 1 2 3 4 5 6 ABSA Healthcare Conference | 11 – 12th February 2021
Slide 6: Southern Africa | Growth, Quality & Value Based Care
6 SOUTHERN AFRICA | GROWTH, QUALITY & VALUE BASED CARE Revenue mix (R million) Immediate plans Future direction of travel ▪ Continue to be nimble and efficient ▪ Patient-centred value based care through the ongoing pandemic ▪ Delivered by multi-disciplinary ▪ Restore the business to pre-COVID teams
Slide 7: International | Stable Diversified Diagnostic Portfolio
7 INTERNATIONAL | STABLE DIVERSIFIED DIAGNOSTIC PORTFOLIO ALLIANCE MEDICAL CONTINUES TO DELIVER UNDERLYING GROWTH ▪ AMG was resilient during FY2020 with c6% revenue growth excluding COVID impact ▪ Continued robust PET-CT scan growth in the UK, albeit at slightly slower rate than previously due to CO
Slide 8: Our Growth Plans in a Pre-COVID World
OUR GROWTH PLANS IN A PRE-COVID WORLD “PLANS ARE OF LITTLE IMPORTANCE, BUT PLANNING IS ESSENTIAL.” Winston Churchill
Slide 9: Growth Initiatives | Southern Africa
9 GROWTH INITIATIVES | SOUTHERN AFRICA Radiology strategy Comparison of scans done by AMG vs SA private sector ▪ Key pillar of future growth 887k 104k 734k ▪ Radiology is a cR8.5 billion private sector market ▪ Public – private opportunities may present additional revenue ▪ Aim to create a national
Slide 10: Growth Initiatives | Life Molecular Imaging (LMI)
10 GROWTH INITIATIVES | LIFE MOLECULAR IMAGING (LMI) NeuraCeqTM ▪ Is an approved amyloid imaging tracer ▪ Used in PET-CT scans to help diagnose Alzheimer’s disease ▪ This diagnostic market opportunity could be c.EUR1 billion in revenue ▪ LMI is in discussions on reimbursement and commercial sales co
Slide 11: Growth Initiatives | Life Molecular Imaging (LMI)
11 GROWTH INITIATIVES | LIFE MOLECULAR IMAGING (LMI) ▪ While LMI’s current focus is on NeuraCeq, LMI also has a pipeline of new products in various stages of development which could bolster its portfolio Dementia / Neurodegeneration Cardiovascular Oncology 68Ga-RM2/ Neuraceq 18F-PI-2620 18F-DED 18F-
Slide 12: COVID-19 Update and Outlook
Li ea Group HEALTH Jy CARE COVID-19 UPDATE AND OUTLOOK
Slide 13: COVID-19 Update | Southern Africa
13 COVID-19 UPDATE | SOUTHERN AFRICA COVID-19 admissions in Life Healthcare facilities COVID-19 impact on PPDs and theatre time 2 500 120 Dec Wave 2 120 000 Hard lock Wave 1 & Dec Wave 2 holidays down holidays peak = 2 074 100 100 000 PPDs and Theatre minutes 2 000 and % of total PPDs no. of COVID P
Slide 14: COVID-19 Update | International
14 COVID-19 UPDATE | INTERNATIONAL ALLIANCE MEDICAL SCAN VOLUMES REMAIN RESILIENT DURING WAVE 2 ▪ While in Wave 1 we saw an initial reduction of 60% to 70% in weekly volumes, there hasn’t been as significant an impact from the 2nd Wave ▪ PET-CT volumes are higher than the prior year, pre COVID-19 ▪
Slide 15: FY2021 Outlook
15 FY2021 | OUTLOOK ▪ Persistent uncertain COVID-19 environment with potential for 3rd and 4th Waves ▪ Business adopting lessons learned from each Covid wave to ensure best practices deployed ▪ Focus remains on treating our patients and looking after our employees, doctors and other COVID-19 healthc
Slide 16: Questions
Life. ...., HEALTH Jy CARE QUESTIONS
Life Healthcare Group Holdings — ABSA Healthcare Conference 2021 on 6ix